CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

212690Orig1s000

PRODUCT QUALITY REVIEW(S)





RECOMMENDATION: Approval

NDA 212690

Review #1

Drug Product Name	XYWAV (calcium, magnesium, potassium and sodium oxybates) oral solution	
Dosage Form	Solution	
Strength	0.5 g/mL Total Salts comprised of: 0.234 g/mL calcium oxybate 0.130 g/mL potassium oxybate 0.096 g/mL magnesium oxybate 0.040 g/mL sodium oxybate (Equivalent to 0.413 g/mL oxybate)	
Route of Administration	Oral	
Rx/OTC Dispensed	/OTC Dispensed Rx	
Applicant	Jazz Pharmaceuticals Ireland Limited	
US agent, if applicable	Jazz Pharmaceuticals, Inc.	


QUALITY TEAM

Discipline	Primary Assessment	Secondary Assessment	
Drug Substance	Gaetan Ladouceur	Donna Christner	
Drug Product	Grace Chiou	Julia Pinto	
Manufacturing	Joanne Wang	Frank Wackes	
Microbiology	Hemlata Tamta	Nandini Bhattacharya	
Biopharmaceutics	N/A	N/A	
Regulatory Business Process Manager	Florence Aisida		
Application Technical Lead	Martha Heimann		
Laboratory (OTR)	N/A	N/A	
Environmental	N/A	N/A	



SUBMISSIONS REVIEWED

Submission	Document Date	Disciplines Affected
SD-01, Original NDA	1/21/2020	All
SD-03, Response to IR	2/4/2020	Manufacturing
SD-04, Response to IR	2/11/2020	Drug Product
SD-05, Response to IR	3/31/2020	Drug Product
SD-06, Response to IR	4/3/2020	Drug Product
SD-10, Response to IR	4/24/2020	Drug Substance, Drug Product, Microbiology



QUALITY ASSESSMENT DATA SHEET

1. RELATED/SUPPORTING DOCUMENTS

A. DMFs:

DMF#		Holder	Item Referenced	Status	Date Assessed	Comments
(b) (4) III		(b) (4)	N/A 1		
	Ш			N/A 1	==	
	III			N/A 1	==	
	Ш			N/A ¹	=	
	-			N/A 1		
	III			N/A 1		

¹ Adequate information in NDA

B. Other Documents: IND, RLD, or sister applications

Document	Application Number	Description
NDA	21196	Approved NDA held by Jazz Pharmaceuticals for Xyrem® (sodium oxybate) oral solution
IND	49641	Development of Xyrem and the proposed mixed oxybate salts product

2. CONSULTS

Not applicable



EXECUTIVE SUMMARY

I. RECOMMENDATIONS AND CONCLUSION ON APPROVABILITY

The Office of Product Quality (OPQ) review team recommends that the Agency **Approve** NDA 212690 for XYWAV (calcium, magnesium, potassium, and sodium oxybates) oral solution. From a quality perspective, the application provides adequate information to ensure that the Applicant can consistently manufacture a product that is suitable for use by the intended patients.

II. SUMMARY OF QUALITY ASSESSMENTS

A. Product Overview

Sodium oxybate (sodium gamma-hydroxybutyrate) was approved in under NDA 21196 in 2002 as Xyrem® (sodium oxybate) oral solution 0.5 g/mL. Xyrem is indicated for treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy. The current holder NDA 21196, Jazz Pharmaceuticals, is seeking approval for an oxybate "mixed salts" oral solution (JZP-258) as a follow-on to the approved product. Due to the high doses used, the Xyrem formulation results in high sodium intake (maximum dose of 9 g sodium oxybate/night is equivalent to 1640 mg sodium). The intent of the JZP-258 formulation is to reduce sodium content by replacing most of the sodium with other cations, i.e., calcium, potassium, and magnesium. By adjusting the relative amounts of each cation, the applicant developed a product that contains the same concentration of the active moiety, oxybate (0.413 g/mL) and a total salt concentration of 0.5 g/mL. Note that although Xyrem and JZP-258 are both simple aqueous solutions that contain the same concentration of the active moiety; the products are not bioequivalent. Therefore, the applicant was required to perform a clinical study to demonstrate efficacy.

Proposed indication(s) including intended patient population	Treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy
Duration of treatment	Chronic
Maximum daily dose	9 g/day
Alternative methods of administration	None

B. Quality Assessment Overview

The proposed product contains an active moiety with a simple chemical structure in a nonsterile aqueous solution. Based on the initial risk assessment, the product was classified as low risk for all critical attributes except palatability and leachables,



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

